Nimotop (Nimodipine)

Nimodipine blocks L‑type calcium channels in the smooth muscle of cerebral arteries. This action limits calcium entry into the cells, causing selective vasodilation of intracranial vessels, improving blood flow and decreasing the likelihood of vasospasm following hemorrhage.

The dose of Nimotop is determined by the prescribing physician based on clinical guidelines and the individual patient's condition. Typical regimens involve oral administration for a defined period after subarachnoid hemorrhage, but exact dosing must be individualized and confirmed by a healthcare professional.

Safety data for nimodipine in pregnancy and lactation are limited. It is generally avoided unless the potential benefit outweighs the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Nimotop product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimodipine is more selective for cerebral vessels than many other dihydropyridine calcium‑channel blockers such as nicardipine or amlodipine, which act more broadly on systemic vasculature. This selectivity makes nimodipine particularly effective for preventing vasospasm after subarachnoid hemorrhage while minimizing systemic blood‑pressure effects.

Nimotop tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources. Keep out of reach of children and dispose of any expired product according to local regulations.

Nimotop is supplied as oral tablets. The tablet should be swallowed whole with a glass of water, with or without food, as directed by the prescriber. Patients should follow the exact schedule provided by their healthcare professional to maintain consistent drug levels.

The most serious adverse events include severe hypotension, bradycardia, allergic reactions such as anaphylaxis, significant liver enzyme elevations, and rare hematologic abnormalities like neutropenia. Patients should seek immediate medical attention if they experience faintness, rapid heartbeat, rash, or signs of liver dysfunction.

Nimotop is contraindicated in individuals with known hypersensitivity to nimodipine or any excipients, patients with severe hypotension, and those with certain cardiac conduction disorders. Caution is also advised for patients with significant hepatic impairment or those taking interacting medications that could cause dangerous blood‑pressure drops.